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Abstract
Background: Visual impairment from diabetic retinopathy (DR) is an increasing global public health concern, which
is preventable with screening and early treatment. Digital retinal imaging has become a preferred choice as it
enables higher coverage of screening. The aim of this review is to evaluate how different characteristics of the DR
screening (DRS) test impact on diagnostic test accuracy (DTA) and its relevance to a low-income setting.
Methods: We conducted a systematic literature search to identify clinic-based studies on DRS using digital retinal
imaging of people with DM (PwDM). Summary estimates of different sub-groups were calculated using DTA values
weighted according to the sample size. The DTA of each screening method was derived after exclusion of
ungradable images and considering the eye as the unit of analysis. The meta-analysis included studies which
measured DTA of detecting any level of DR. We also examined the effect on detection from using different
combinations of retinal fields, pupil status, index test graders and setting.
Results: Six thousand six hundred forty-six titles and abstracts were retrieved, and data were extracted from 122
potentially eligible full reports. Twenty-six studies were included in the review, and 21 studies, mostly from high-
income settings (18/21, 85.7%), were included in the meta-analysis. The highest sensitivity was observed in the
mydriatic greater than two field strategy (92%, 95% CI 90–94%). The highest specificity was observed in greater
than two field methods (94%, 95% CI 93–96%) where mydriasis did not affect specificity. Overall, there was no
difference in sensitivity between non-mydriatic and mydriatic methods (86%, 95% CI 85–87) after exclusion of
ungradable images. The highest DTA (sensitivity 90%, 95% CI 88–91%; specificity 95%, 95% CI 94–96%) was
observed when screening was delivered at secondary/tertiary level clinics.
Conclusions: Non-mydriatic two-field strategy could be a more pragmatic approach in starting DRS programmes
for facility-based PwDM in low-income settings, with dilatation of the pupils of those who have ungradable images.
There was insufficient evidence in primary studies to draw firm conclusions on how graders’ background influences
DTA. Conducting more context-specific DRS validation studies in low-income and non-ophthalmic settings can be
recommended.
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Background
Diabetes mellitus (DM) is one of the most prevalent
non-communicable diseases and has significant impacts
on health systems [1]. The International Diabetes Feder-
ation (IDF) estimated that there were 425 million people
with DM (PwDM) in the world in 2017 which is projected
to increase to 629 million by 2045 [2]. The greatest impact
affects low- and middle-income countries (LMIC) (overall
increase 69%) due to ageing population, obesity and sed-
entary life style [3]. This is exacerbated by weak health
systems coupled with slow economic development [4].
Diabetic retinopathy (DR) is a common microvascular
complication of DM caused by chronic hyperglycaemia
[5]. A pooled meta-analysis using population-based
studies conducted in the USA, Australia, Europe and Asia
showed that the prevalence of any DR in PwDM aged 20
to 70 years was 34.6% (95% CI 34.5–34.8%): proliferative
DR affected 6.96% (95% CI 6.87–7.04%) and sight-threat-
ening DR (STDR) affected 10.2% (95% CI 10.1–10.3%),
globally translating to approximately 28 million PwDM af-
fected by STDR [6]. DR is a leading cause of blindness
among the young and middle-aged adults in most of the
high-income countries (HIC).
Many studies have shown that control of risk factors,
early DR screening (DRS) and appropriate treatment can
reduce the risk of blindness and visual impairment due
to DR [7–12]. Digital retinal imaging has been widely
practiced and an accurate method for DRS [13]. Provid-
ing appropriate training to photographers is of para-
mount importance, and with enough practice, high
levels of competence can be achieved by those taking
imaging regularly. Non-mydriatic digital imaging
methods cause less discomfort and are more convenient
for service providers. However, poor image quality is an
important limitation of digital retinal imaging, particu-
larly if non-mydriatic systems are being used, in coun-
tries where cataract is common [14].
In current literature, a systematic review showed that
dilated imaging aided by fundoscopy for ungradable im-
ages was an effective modality to screen for DR [15].
This review included studies from 1985 to 1998 when
digital retinal imaging technology was not available. Shi
et al. concluded that accuracy of detecting presence/ab-
sence of DR by tele-medicine using digital imaging is
high (pooled sensitivity 80%, 95% CI 84–88%; pooled
specificity 89%, 95% CI 88–91%) [16]. Another meta-
analysis concluded that dilatation of the pupils did not
have a bearing on the diagnostic test accuracy (DTA) for
any level of DR (sensitivity: odds ratio (OR) − 0.89, 95% CI
0.56–1.41, p = 0.61; specificity: OR 0.94, 95% CI 0.57–1.54,
p = 0.80) [17]. A limitation of this review was that results
from different imaging methods (i.e. polaroid, film and
digital) and clinical examination were pooled into one
estimate.
A DRS modality which is suited to the health system
and its context is a key factor in the success of a
programme [18]. A screening programme requires sub-
stantial investment in infrastructure and workforce devel-
opment. LMICs have low capacity to implement a
population-based DRS programme (DRSP) with routine
call/recall and full DR patient list. Yet there is a high bur-
den of unmet need, with higher levels of uncontrolled DM
leading to higher rates of DR progression. Weak health
systems require a DRSP where detection of any DR using
most effective and efficient instruments would be most
useful. In addition, resources are scarce, and so efficient
use of both equipment and human resources are essential.
The detection of clinic-based PwDM with any DR will en-
able identification and stratifying risk groups early and
screen safely at a lower threshold at non-ophthalmic set-
tings. Therefore, a feasible way of providing accessible ser-
vices is to offer digital photographic DRS when PwDM
present for routine medical care at diabetologist/physi-
cians’ clinics. In a low-income setting, identification of a
person with any DR/no DR would be a helpful stratifica-
tion for the providers. In a practical programme guideline,
we would suggest performing mydriatic imaging or refer
to the next level for those with ungradable images. There
is also a lack of understanding among the PwDM about
the benefits of mydriasis. Discomfort experienced after
pupil dilatation has led to low uptake in dilated examin-
ation [19]. Therefore, it is important to understand the
best method to detect any DR in non-specialist settings
that will be suited to LMICs [18].
The objectives of this review were to evaluate how
using or not using pharmacological dilation of the pupil
and the number of fields captured influence DTA and
how well different ophthalmic and non-ophthalmologist
health care professionals perform DR grading compared
to seven-field image grading or mydriatic ophthalmos-
copy by ophthalmologists in different clinical settings.
This will inform decision-making for choosing strategy
in those aspects of a DRSP. This is an assessment of ac-
curacy of instruments for a systematic clinic-based
screening rather than a population-based screening tool.
We plan to propose most efficient modality for provision
of DRS to PwDM at non-ophthalmic settings (i.e., med-
ical clinic, endocrinology clinic) using this evidence.
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-Analysis (PRISMA) guidelines were followed
in reporting (The PRISMA checklist is available as
Additional file 1).
Eligibility criteria and study context
We included studies of cross-sectional study designs that
aimed to evaluate the accuracy of DRS using digital
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imaging as the index test, in PwDM at permanent
healthcare facilities. We used the Early Treatment Dia-
betic Retinopathy Study (ETDRS) seven-field image in-
terpretation as the gold standard and mydriatic
bio-microscopy/ophthalmoscopy by an ophthalmologist/
retinologist as the clinical reference standard where the
gold standard was not performed. The primary context
considered for this review was institutional DRS clinics/
programmes using digital imaging. We categorised the
context as either primary or secondary/tertiary. We ex-
cluded studies conducted in informal health facilities,
used automated analysis systems, used non-digital im-
aging methods in index test, used mobile screening
methods or did not report on DTA as an outcome
measure.
Primary outcome
The outcome examined was sensitivity and specificity of
detection of ‘any level of DR’. It is important to under-
stand the optimal method to detect any DR in
non-specialist settings, especially in LMICs where
PwDM have higher risk of progression, due to poorly
controlled risk factors and irregular follow up. ‘Any level’
of DR was considered appropriate as we felt that such
an approach would have collateral benefits like raising
awareness among the providers as well as augmenting
awareness of PwDM regarding the importance of regular
follow-up and control of the risk factors minimising the
progression to STDR.
Search and study selection
We developed a comprehensive search strategy to obtain
published articles by consulting an information specialist
and searched MEDLINE (Ovid), Cochrane Database of
Systematic reviews (CDSR) and CENTRAL in the
Cochrane Library. The databases were searched from
the date of inception of the databases to September
2016, to identify any published reviews on this topic and
to see whether relevant trials where included in the
CENTRAL database. The search terms and strategy are
shown in Table 1 and Fig. 1 respectively. Two reviewers
(PN and SK) independently assessed the eligibility of the
titles and abstracts, and discrepancies were solved by
consulting a third reviewer (GV). Full papers of the eli-
gible articles (n = 122) were obtained from the pub-
lishers/authors.
Data collection process
A data extraction form was prepared, and data were ex-
tracted and entered into a formatted MS Excel® database.
Data from all the full reports of filtered citations (n =
122) were extracted. We used a modified Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines for cross-sectional studies to
identify the components to extract [20]. The modifica-
tions made were based on Cochrane guidelines on con-
ducting systematic reviews of studies of DTA [21]. Two
independent reviewers extracted the data (PN and SK)
from full reports. In the piloting stage, data were ex-
tracted from 10% (12/122) of the articles by two re-
viewers and consistency was checked (SH). Corrections
to the data extraction sheets and databases were done at
this stage. The data extracted of all the included articles
(n = 26) were checked by the co-reviewer (SK) for
consistency.
Data items
The data extracted from each study included country,
study design, study setting, sample size and participant
characteristics (mean age with standard deviation and
range, male to female ratio, number of years with DM).
The next section of the extraction included study objec-
tives, sampling strategy, methods of index test (degree of
view, number of fields, pupil status and type of camera)
and method of reference standard. Finally, data on DTA
(sensitivity with 95% CI, specificity with 95% CI, number
of true positives, true negatives, false positives and false
negatives, kappa value and gradability) were extracted.
Studies were categorised according to the status of pu-
pils, number of fields in imaging, type of index test
grader and type of reference standard.
Meta-analysis
Meta-analysis of the data was conducted to examine
differences in outcome due to pupil status (mydriatic
and non-mydriatic), number of retinal fields (one field,
two fields, greater than two fields), type of index test
grader (ophthalmologist, retinologist, retinal reader,
ophthalmic registrars) and by the context (primary and
Table 1 Electronic database search terms
1. Exp mass screening/
2. Exp vision tests/
3. Exp telemedicine/
4. Exp Photography/
5. Exp ophthalmoscopes/
6. Exp ophthalmoscopy/
7. (ophthalmoscop$ or
fundoscop$
or funduscop$) . ti .
8. ((photo$ or imag$) adj3
fundus) . tw .
9. (Photography or
retinopgraphy) . tw .
10. ((mydiatric or digital or
retina$ or funduc or
stereoscopic) adj3
camera) . tw .
11. ((mydiatric or digital
or retina$ or fundus or
stereoscopic) adj3 imag$) .tw .
12. Screen$ . tw .
13. ((eye$ or retina$ or ophthalm$)
adj4 exam$).tw .
14. ((eye$ or vision or ophthalmic)
adj4 test$) . tw.
15. ((eye$ or retina$ or ophthalm$)
adj4 visit$) . tw .
16. Office visits/
17. (telemedicine$ or telemonitor$
or telescreen$) . tw .
18. 1 or 2 or 3 or 4 or 5 or 6 or 7
or 8 or 9 or 10 or 11 or 12 or
13 or 14 or 15 or 16
19. exp diabetes mellitus/
20. exp diabetes complications/
21. 19 or 20
22. exp diabetic retinopathy/
23. ((diabet$ or proliferative or
non-proliferative) adj4
retinopath$).tw.
24. 21 or 22
25. 18 and 21 and 24
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secondary/tertiary). A sub-group meta-analysis was
undertaken to determine the DTA of ‘any level’ of DR
by non-ophthalmic personnel. Further sub-analyses
were conducted by considering the studies which re-
ported on DTA using the same participant imaged be-
fore and after pupil dilatation.
Risk of bias in individual studies
We assessed the variations in bias using the Quality as-
sessment of diagnostic accuracy studies - 2nd version
(QUADAS-2) framework [22]. The methodological qual-
ity and applicability of the studies was considered using
signalling questions under the four domains of patient
selection, index test, reference standard and flow and
timing [22]. We examined the differences in reported
DTA estimates based on QUADAS-2 quality assessment
guidelines, and given results in the meta-analysis were
based on the studies identified to have low risk of bias.
The methodological quality of the studies included in
the review and meta-analysis are described in Table 2.
All included studies were cross sectional in design as
these demonstrated less bias in the QUADAS assess-
ment. We considered the signalling questions according
to the QUADAS-2 guidelines as examples, masking of
the graders, inclusion of range of spectrum to reduce
the spectrum bias, all participant undertaking all tests
etc. when assessing the bias.
Synthesis of results
Meta-analysis was conducted using STATA/IC (ver-
sion-14.1, 2015-Texas-77845-USA) after acquiring the
2 × 2 table (TP, FP, TN and FN) values for number of
eyes screened as the unit of analysis in each method of
DRS. These values were cross checked by the number of
Fig. 1 PRISMA flow diagram of the study selection process
Fig. 2 Proportion of included studies with a risk of bias
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DR positives and negatives reported in classification of
findings under different categories of DR. The
meta-analysis was conducted using the DTA of any DR,
after excluding the ungradable images. Sub-analyses
were conducted using the estimates that reported DTA
on same participant groups before and after pupil dilata-
tion and by non-ophthalmic index test graders.
Heterogeneity was assessed between the studies and
between different modalities in the same study. Due to
differences in definitions of the ungradable image cat-
egory, we decided to exclude all ungradable images to
minimise heterogeneity. At a practical programme level,
all PwDM with ungradable images will be referred to the
ophthalmologist’s clinic for further assessment. However,
in this study, we were interested in the accuracy of the
intervention to detect any DR, rather than any referable
PwDM in a programme model.
Results
The electronic database search yielded 6646 titles and
abstracts, and 122 studies were selected to review full re-
ports. Twenty-six studies were included in the review
(Fig. 1). The details of the excluded articles are available
as Additional file 2. We included 26 cross-sectional
studies, and 88% (23/26) were conducted in HICs [23–
45]. The remaining studies (3/26, 11%) were conducted
in South East Asian upper middle-income countries
(Thailand (one) [46], China (one) [47] and Taiwan (one)
[48]). There were 6 studies (10 estimates) which re-
ported DTA in which the same participant underwent
imaging before and after pupil dilatation [25, 35, 40, 42,
44, 47].
The mean sample size of the studies was 316 PwDM
screened (SE± 72.3, 95% CI 166–467, range 51–1549).
Thirty percent (8/26) of studies selected participants
Table 2 Methodological quality and applicability assessment of the included studies (using QUADAS-2 guidelines)
Domains Risk of bias Applicability concerns
Study Patient selection Index test Reference standard Flow and timing Patient selection Index test Reference
standard
1. Ahmed, J. et al. 2006 Low Low Low High High Low Unclear
2. Aptel, F. et al. 2008 Low Low Low Unclear Low Low Low
3. Baeza, M. et al. 2009 High Low Low Low Low Low Low
4. Boucher, M. C. et al. 2003 Low Low Low High High High Low
5. Ding, J. et al. 2012 Low Low Low Low Low High Low
6. Hansen, A. B. et al. 2004 High Low Low Low Low Low Low
7. Henricsson, M. et al. 2000 Low Low Low Unclear Low Low Low
8. Herbert, H. M. et al. 2003 Low Low Low Low Low High Low
9. Ku, J. J. et al. 2013 Low Low Low Unclear High Low Low
10. Kuo, H. K. et al. 2005 Low Low Low Low High Low Low
11. LopezBastida, J. et al. 2007 Low Low Low Unclear Low Unclear Low
12. Maberley, D. et al. 2002 Low Low Low Low High High Low
13. Massin, P. et al. 2003 Unclear Unclear Low Low High High Low
14. Murgatroyd H et al. 2003 Low Low Low Low Low Low Low
15. Neubauer, A. S. et al. 2008 Low Low Low Unclear Low Low Low
16. Olson, J. A. et al. 2003 Unclear Low Low Unclear Low Low Low
17. Phiri, R. et al. 2006 Unclear Low Low Low Low High Low
18. Scanlon, P. H. et al. 2003 Low Low Low Low High High Low
19. Scanlon, P. H. et al. 2003_(2) Low Low Low Low Low High Low
20. Suansilpong, A et al. 2008 Low Low Low Low Low Low Low
21. Sundling, V. et al. 2013 Low Low Low Low Low Low Low
Studies excluded in meta-analysis
22. Bhargava, M. et al. 2012 High High High Unclear Low High Low
23. Mizrachi, Y. et al. 2014 High High High High High High Low
24. Perrier, M. et al. 2003 High Low Low High High High Low
25. Schiffman, R.M. et al. 2005 Low High High Unclear Low High High
26. Tu, K.L. et al. 2004 High High High Low Low High Low
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from local and regional primary care units. Other studies
recruited PwDM from retinal care (5/26, 19.2%), dia-
betes care (4/26, 15.3%), existing DR screening pro-
grammes (4/26, 15.3%), medical and ophthalmology care
(1/26, 3.8%), retinal and ophthalmology care (1/26,
3.8%), ophthalmology care (1/26, 3.8%) and private sec-
tor optometry network (1/26, 3.8%). One study did not
report the setting (1/26, 3.8%). The mean age of partici-
pants was 57.4 years (SE± .52, 95% CI 54.3–60.7, range 16–
89 years): the mean age of participants in non-mydriatic
strategies 58.9 years and mydriatic 59.0 years. The mean
duration of known diabetes among participants was
12.0 years (SE ± 1.5, 95% CI 8.8–15.3 years), and 50.5%
were male (SE ± 2.7, 95% CI 44.8–56.3). Participants’ char-
acteristic tables of the studies included in this review are
available as Additional file 3.
Meta-analysis
Of these 26 studies, 5 studies (5/26, 19.2%) were not eli-
gible for the meta-analysis. Those were excluded from
the meta-analysis due to unavailability of required 2 × 2
table data, very high level of bias and heterogeneity. The
study conducted by Perrier et al. used the same partici-
pants as in the study by Boucher et al. which has been
included and another study was excluded due to a high
likelihood of bias [33, 36]. The study conducted by
Schiffman et al. was excluded as index test pupil status
and number of retinal fields were not mentioned [30].
Two further studies were excluded: one only reported
DTA for STDR [41] and another from Singapore (Bhar-
gava et al.) did not provide DTA data [34].
Among 21 studies included in the meta-analysis, 39 dif-
ferent modalities were identified in terms of pupil status,
retinal field strategy and human resources involved in
index test DR grading. Forty-six percent (18/39 modal-
ities) of the studies used non-mydriatic methods (13/21
studies) [25, 26, 29, 31, 35, 38, 40, 42, 44, 45, 47–49], 44%
(17/39 modalities) used mydriatic methods (11/21 studies)
[23–25, 32, 35, 37, 39, 40, 42, 44, 47] and ophthalmic
personnel currently trained and practiced in DR grading
had performed index test grading in these studies. In 10%,
4/21 [27, 28, 46, 48] newer non-ophthalmologist
personnel had performed index test grading. Six studies
reported mydriatic and non-mydriatic methods (6/21) [25,
35, 40, 42, 44, 47]. One study reported DTA values for
ophthalmic and non-ophthalmic personnel [48]. The DTA
of each screening strategy is available in Additional file 4.
Studies included in secondary output analysis
Four studies were eligible for secondary output of meta-
analysis of DTA of DRS as they used different
non-ophthalmologist personnel [27, 28, 46, 48]. However,
there were no adequate number of studies to meta-analyse
by pupil status and field strategy. The details of these studies
are described in Additional file 3 (participants’ characteris-
tics) and Additional file 4 (DTA).
Risk of bias and applicability concerns within studies
The methodological quality and applicability assessment
of the included studies (Table 2) were according to the
QUADAS-version 2 guidelines. In the assessment of
bias, it was minimal (15.38% high risk) in conducting the
index tests and reference tests. Nineteen percent of the
studies showed high risk of bias in selection and 30.7%
in participant flow and timing (Fig. 2). In the assessment
of applicability, risk was minimal in reference standard
(3.8%) and 34% of the studies showed high risk in applic-
ability with regard to patient selection and 50% in index
test (Fig. 3).
Risk of bias in the included studies
There was selection bias in some studies: Baeza et al. ex-
cluded patients who had visited an ophthalmologist within
6 months of screening and those with hyper-mature cata-
ract [44] and Boucher et al. purposively selected partici-
pants who had a greater risk DR [31]. There were also
applicability concerns when authors reported the DTA of
referable level of DR [38–40, 43, 47]. The study conducted
by Hansen et al., which selected people with diabetes
through a record review, was weighted towards less severe
retinopathy, as mentioned by the authors [25]. Two stud-
ies attempted non-mydriatic methods and ended up dilat-
ing the pupils due to high proportion of ungradable
images [23, 32]. In the study by Lopez-Bastida et al., the
time interval between the index and reference tests was
not stated, nor whether participants with ungradable im-
ages (90/773, 10%) underwent mydriasis while performing
the index test [45]. Similarly, time and flow was not men-
tioned in the study by Ku et al. [37]. Two studies selected
indigenous populations which lead to generalizability con-
cerns [32, 37]. Furthermore, some studies were conducted
in eye/retinal clinics where there was a possibility of high
prevalence of advanced DR [39, 43, 48].
Reporting of DR was not uniform. In several studies,
DTAs were reported for different levels of DR leading to
Fig. 3 Proportion of included studies with applicability concerns
Piyasena et al. Systematic Reviews           (2018) 7:182 Page 6 of 18
some heterogeneity [25, 26, 31, 38–40, 43]. In these stud-
ies, we considered results for the detection of any level of
DR. For example, Phiri et al. had defined DR including the
macular signs which other authors had not considered
and which would have an impact on the analysis [38].
Diagnostic test accuracy in non-mydriatic imaging
Among the 21 studies included in the meta-analysis, 18
used the following non-mydriatic imaging strategies: one
field (8/18, 44.4%), two fields (4/18, 22.2%) and greater
than two fields (6/18, 22.2%). The pooled sensitivity of
detection of any level of DR using non-mydriatic digital
imaging was 86% (95% CI 85–87%). The two-field
strategy gave the highest estimate of sensitivity of 91%
(95% CI 90–93%). The one and greater than two field
strategies gave summary estimates of sensitivity of 78%
(95% CI 76–80%) and 88% (95% CI 86–91%), respect-
ively (Fig. 4, Table 3). The mean proportion of ungrad-
able images in non-mydriatic methods was 18.4% (SE ±
2.2, 95% CI 13.6–23.3%). The summary estimate of spe-
cificity of detection of any level of DR using
non-mydriatic digital imaging was highest in the
two-field and greater than two field strategies (94%, two
field 95% CI 93–95%, greater than two field 95% CI 93–
96%). The one-field strategy gave pooled specificity
values of 91% (95% CI 90–92%) (Fig. 5 and Table 3).
Diagnostic test accuracy in mydriatic imaging
The highest pooled sensitivity of detection of any level of DR
using different mydriatic digital imaging field strategies was
for the greater than two field strategy (92%, 95% CI 90–94%).
The sensitivity of the one-field strategy was 80% (95% CI
77–82%), and it was 85% (95% CI 84–87%) for the two-field
strategy (Fig. 6, Table 3). The mean proportion of ungradable
images for the mydriatic method was 6.2% (SE± 2.2, 95% CI
1.7–10.8%). The summary estimation of specificity in
Fig. 4 Forest plot of summary estimates of sensitivity of non-
mydriatic imaging using different field strategies (1: one field, 2: two
fields, 3: greater than two fields)
Fig. 5 Forest plot of summary estimates of specificity of non-mydriatic imaging using different field strategies (1: one field, 2: two fields, 3: greater
than two fields)
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detection of any level of DR using mydriatic digital imaging
was highest in the greater than two field strategy at 94%
(95% CI 93–96%) followed by the one field, 93% (95% CI
92–94%) and then two field 82% (95% CI 81–83%) (Fig. 7,
Table 3).
Hierarchical summary receiver operating characteristics
(HSROC) curve interpretation
Both non-mydriatic and mydriatic strategies showed very
high discriminative power in ruling out the presence or
absence of any level of DR with the diagnostic odds ratio
(DOR) of non-mydriatic strategies being 68.03 (95% CI
35.5–130.0) and positive likelihood ratio of 11.79 (SE
3.04, 95% CI 7.1–19.5) (Fig. 8). Similarly, mydriatic DOR
was 53.98 (95% CI 31.1–93.5) and the positive likelihood
ratio was 9.5 (SE 2.1, 95% CI 6.1–14.7) (Fig. 9). After
adjusting for ungradable images, we observed that the
pooled sensitivity of detection of any level of DR was the
same for non-mydriatic and mydriatic strategies: 86%
(95% CI 85–87%) for both. The specificity of detection
of any level of DR was higher using both non-mydriatic and
mydriatic greater than two field strategies (94%, 95% CI 93–
96%) and in two-field non-mydriatic strategy (94%, 95% CI
93–95%). The highest DOR was obtained for the greater
than two field strategy (non-mydriatic DOR 182.4 (SE 145.2,
95% CI 38.3–868.5), mydriatic DOR 140 (SE 76.1, 95% CI
48.2–406.7)). Therefore, we have to consider the number of
fields in a DRS strategy (Fig. 10 and Additional file 5).
Summary estimates were derived by the reference test, to
assess the variability in DTA according to the reference
standard. The pooled sensitivity of detection of any level of
DR was higher in non-mydriatic imaging using seven-field
ETDRS images as the reference than direct/indirect oph-
thalmoscopy: (87%, 95% CI 85–89% vs 86%, 95% CI 85–
88% in mydriatic). There was no significant difference when
compared with mydriatic bio-microscopic ophthalmoscopy
as the reference standard (non-mydriatic 86%, 95% CI 85–
88% vs mydriatic 86%, 95% CI 85–87%). Pooled estimates
of specificity were high in both non-mydriatic (96%, 95% CI
95–97%) and mydriatic (96%, 95% CI 95–97%) imaging
using seven-field ETDRS images as the reference standard
compared to mydriatic bio-microscopy (non-mydriatic
91%, 95% CI 91–92 vs mydriatic 87%, 95% CI 86–88%)
(Table 3 and forest plots available in Additional file 6).
In the analysis of DTA by setting, the highest estimates
were shown in secondary/tertiary settings using non-
mydriatic imaging (sensitivity 90%, 95% CI 88–91; specifi-
city 95%, 95% CI 94–96%) compared to mydriatic imaging
(sensitivity 87%, 95% CI 86–89%; specificity 89%, 95% CI
88–90%) (Table 4). However, in non-mydriatic methods,
Fig. 6 Forest plot of summary estimates of sensitivity of mydriatic imaging using different field strategies (1: one field, 2: two fields, 3: greater
than two fields)
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there was one study from HIC with a larger sample size,
which may have attributed for a skewed result (40).
Regarding the personnel involved in index test grad-
ing, for ‘any level’ of DR, the highest pooled sensitivity
and specificity using non-mydriatic imaging was re-
ported by retinologists: sensitivity 90% (95% CI 89–92%)
and specificity 94% (95% CI 93–95%). The highest DTA
estimates in mydriatic imaging were reported by oph-
thalmologists (sensitivity 87%, 95% CI 85–89%; specifi-
city 93%, 95% CI 92–94%) (Table 4 and forest plots
available in Additional file 7).
Secondary output
In the sub-analysis of those studies that captured images
of the same participant before and after pupil dilatation,
mydriasis (one field, two fields, three fields and five field:
six studies, ten estimates) showed a high level of sensitiv-
ity: mydriatic 88% (95% CI 86–89) and non-mydriatic 82%
(95% CI 80–84%). However, a higher level of specificity
was shown in non-mydriatic methods in detecting any
level of DR: non-mydriatic 92% (95% CI 91–93%) and
mydriatic 89% (95% CI 88–90%). Forest plots of these esti-
mates are available in Additional file 8. Four studies used
non-ophthalmologist personnel as primary graders in the
index test. The pooled sensitivity and specificity of
detecting any level of DR (either non-mydriatic or mydri-
atic) were 74% (95% CI 71–77%) and 85% (95% CI 83–
87%) respectively (27, 28, 46, 48).
Discussion
Overall, both mydriatic and non-mydriatic digital imaging
methods generate a satisfactory level of sensitivity, i.e. 86%
(95% CI 85–87%) in usual clinical settings, once ungrad-
able images are excluded from analysis. This sensitivity
level is above the DRS recommendation of established na-
tional programmes (sensitivity > 80%) [50]. Neither strat-
egies achieved the recommended level of 95% specificity
for any level of DR: non-mydriatic 95% CI (92–93%) and
mydriatic 95% CI (89–90%). In addition, mydriatic greater
than two field strategy showed the highest level of sensitiv-
ity (92%, 95% CI 90–94) and specificity (94%, 95% CI 93–
96%), a finding to be considered when setting up a screen-
ing strategy.
The optimum level of referable DR will depend on the ac-
curacy of the screening strategy chosen and the resources
available in the specific screening setting in order to strike a
balance between screening PwDM at non-ophthalmic set-
tings safely, but without overloading the eye clinics for fur-
ther assessments. Annual DRS, followed by timely treatment
Fig. 7 Forest plot of summary estimates of specificity of mydriatic imaging using different field strategies (1: one field, 2: two fields, 3: greater
than two fields)
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of those confirmed to have STDR is the recommended
screening pathway [51]. The current method of DRS in most
LMICs is an opportunistic screening using mydriatic
bio-microscopic ophthalmoscopy by an ophthalmologist
[18]. This is not an efficient way of screening for DR consid-
ering the limitations in human resources and access barriers.
In contrast, DRS using digital imaging requires specific train-
ing and skills, but these can be obtained by non-medical
personnel, and as such the pool of potential workforce is
much larger than for trained ophthalmologists.
In this meta-analysis, we aimed to show the effect of
pupil status on DTA for any DR. For those images sets
with gradable images, the pooled sensitivity of non-
mydriatic strategies was the same as that of the mydri-
atic strategies. However, only six studies (6/21) used the
same participants before and after pupil dilatation [25,
35, 40, 42, 44, 47]. The non-mydriatic method results
were primarily dominated by one larger study (sample
size n = 1549) conducted in a HIC [40] and another
study used wide field (Optomap® 180–200° field view)
imaging [26]. Therefore, the outcome of this review
should be applied to LMICs cautiously. A similar result
was reported in a meta-analysis by Bragge et al. although
heterogeneity among those studies was high due to pool-
ing of different examination techniques in one estima-
tion [17]. In the current meta-analysis, heterogeneity
was minimised by including studies which used digital
retinal imaging only in the index test.
A DRS method which is suited to the health system is a
key factor in the success of a programme. Non-mydriatic
imaging can be used in settings where there are fewer
ophthalmic personnel and avoiding pupil dilatation re-
duces screening time and causes less perceived inconveni-
ence to PwDM. A concern, however, is variability in image
quality, particularly in populations with a high prevalence
of cataract and corneal opacities [14, 52]. The Scottish Na-
tional Health Services DRSP now uses non-mydriatic im-
aging systems, with minimal need for pupil dilatation in
screened patients [53]. This is an evidence-based prag-
matic approach with greater convenience for PwDM and
lower cost to service providers [54, 55]. However, imple-
mentation of non-mydriatic test in DRS will depend on
population characteristics such as the prevalence of
cataract.
Fig. 8 HSROC curve in non-mydriatic imaging strategies
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Selection of suitable personnel for DRS and grading
depends on workforce capacity and availability. DRS by
ophthalmologists is not an efficient way of screening for
any setting [55]. DM-related blindness is still on the rise
everywhere in the world and is a public health concern
in LMIC settings as well [18]. These countries will have
to rapidly adopt clinically safe and cost-effective strat-
egies to address this issue, using the limited resources
available and establish such a programme quickly [56].
In this analysis, retinal image graders could achieve the
recommended level of 80% sensitivity and specificity
closer to 95% in both mydriatic and non-mydriatic strat-
egies. Therefore, it is justifiable to train non-ophthalmic
personnel in DR grading, just as it was done in the UK
national programme.
DR screening’s success depends on the gradability of
images, as such most of the studies included only grad-
able images. High population coverage with good quality
gradable images is an important pragmatic consideration
to achieve high DTA and high acceptability of a DRSP.
Therefore, interpretation of the results shown in this
study requires judgement of the context and objectives
of a specific DRSP. PwDM with ungradable images are a
special category of people whose fundus is not visible
due to some other ocular pathology like dense lenticular
opacities. These people therefore not only need the
management that test negatives receive in terms of
management of diabetic retinopathy but will also need
additional management of ocular pathology which is
obliterating the fundus image. Therefore, this meta-
analysis highlights the concerns as to how to manage
data on ungradable images, as studies differ in their ap-
proach of dealing with such a concern. Most authors
(13 studies) had excluded ungradable images from their
analysis while others included them as having screened
positive (six studies). In addition, reporting of ungra-
dable by study authors was heterogeneous, which imply
requirement of standardised reporting of ungradable
images in DRS.
The mean proportions of ungradable images in non-
mydriatic and mydriatic imaging were 17.8% (95% CI 10.8–
24.8%) and 6.1% (95% CI 3.7–8.4%) respectively. The deci-
sions made by each study authors may have introduced
reporting bias in their measures of DTA. Considering
Fig. 9 HSROC curve in mydriatic imaging strategies
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ungradable images as test positives may have led to in-
flated estimates of DTA in some studies [25, 26, 40,
42–44]. The mean proportions of ungradable images
included by study authors as test positives in
non-mydriatic and mydriatic imaging were 12.5% (95%
CI 9.0–16.1%) and 2.5% (95% CI 1.0–3.9%) respectively.
Therefore, we adjusted DTA to take account of ungrad-
able images by excluding those to reduce heterogeneity.
This was possible for four of the six studies in which
ungradable images were included as screening positive
[25, 26, 40, 43], but two did not report adequate data to
allow for this [42, 44]. As an example, we made adjust-
ment (calculated sensitivity 42/49 = 85.7%, specificity
227/262 = 86.6%) for the inflated DTA (reported sensitivity
98%, specificity 100%) in the study of Ahmed et al. using
the 2 × 2 table data reported by study authors [29]. In
another two studies, it was not clear how ungradable im-
ages had been managed [28, 38]. The proportions of
ungradable images and DTA after adjustments in each
strategy are available in Additional file 9.
Limitations
The definition of ungradable images was not uniform in
the studies included in the current review We minimised
the heterogeneity by excluding the ungradable images
and by sub-group analysis.
The studies which used non-mydriatic imaging tech-
niques were more recent, being conducted after rapid
advancements in technology for such imaging technol-
ogy leading to better quality images using non-mydriatic
systems without pupil dilatation as well and a major
confounder in the meta-analysis.
Fig. 10 HSROC curves by field strategy and pupil status
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The results of the different strategies described in
this review are to be considered fully if a comprehen-
sive DRSP facilitating greater screening coverage with
improved accessibility and good quality imaging is to
be set up. However, due to lack of relevant good
quality data, sub-analysis by countries’ income setting
was not possible to perform due to absence of studies
from LMICs.
We excluded three articles which were not in English
due to practical barriers in translations and assessment
of methodological quality.
The DTA of detection of maculopathy had not been
considered. The maculopathy is also an important as-
pect in DRS, and it may have to be considered in a
separate review.
Conclusions
Diagnostic test accuracy for the detection of any level of
DR showed that DRS using two fields delivered at
non-primary care settings is a feasible approach. Dilata-
tion of the pupils did not improve the detection of any
level of DR for those with gradable images, but such a
wide range of ungradable were presented in these studies
that this aspect must be taken into account when setting
up DRSP. There was no adequate evidence in primary
studies to comment on DTA of non-ophthalmological
human resources on DRS, so this aspect requires further
research. Good quality digital imaging has the potential
for real-time interpretation of retinal images, which
together with counselling for risk factors may improve
the acceptability of DRS and uptake of referral for
ophthalmic assessment if conducted in a culturally ac-
ceptable way.
Recommendations
Diagnostic test accuracies of the newer non-mydriatic
imaging systems should be further explored in different
environments and using a different skill-mix of graders,
especially in LMICs.
Studies should focus on the accuracy of non-ophthalmic
graders and non-ophthalmic settings to explore the poten-
tial of initiating DRSP especially in low-income settings.
This will reduce the number of referrals to eye depart-
ments, many of which are already over-burdened with
cataract and other eye conditions, particularly in LMIC
where resources are limited.
The reporting definitions of technical failures or
ungradability of the images should be standardised using
a reporting guideline.
A systematic review and meta-analysis of DTA of dif-
ferent levels of DR and maculopathy can be recom-
mended in future research.
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